標(biāo)題: Titlebook: Biomarkers in Breast Cancer; Giampietro Gasparini,Daniel F. Hayes Book 2006 Humana Press 2006 DNA.classification.gene expression.systemic [打印本頁] 作者: Forestall 時(shí)間: 2025-3-21 18:06
書目名稱Biomarkers in Breast Cancer影響因子(影響力)
書目名稱Biomarkers in Breast Cancer影響因子(影響力)學(xué)科排名
書目名稱Biomarkers in Breast Cancer網(wǎng)絡(luò)公開度
書目名稱Biomarkers in Breast Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomarkers in Breast Cancer被引頻次
書目名稱Biomarkers in Breast Cancer被引頻次學(xué)科排名
書目名稱Biomarkers in Breast Cancer年度引用
書目名稱Biomarkers in Breast Cancer年度引用學(xué)科排名
書目名稱Biomarkers in Breast Cancer讀者反饋
書目名稱Biomarkers in Breast Cancer讀者反饋學(xué)科排名
作者: nutrition 時(shí)間: 2025-3-21 22:25 作者: PANG 時(shí)間: 2025-3-22 00:29
Urokinase-Type Plasminogen Activator and PAI-1 factors has the potential to result in the enhanced management of patients with breast cancer. Measurement of these analytes should thus be now considered for use in the routine management of patients with breast cancer.作者: 培養(yǎng) 時(shí)間: 2025-3-22 07:22
Predictive Value of c-,B2 for Endocrine Therapy and Chemotherapy in Breast Cancer, other regimens should not be withheld from women who cannot receive an anthracyline. Current clinical data also suggest a possible sensitivity to taxane-based therapy, especially when combined with an anthracycline. Trastuzumab-based therapy should be considered as first line therapy for women wit作者: hemoglobin 時(shí)間: 2025-3-22 12:16 作者: mastoid-bone 時(shí)間: 2025-3-22 13:41 作者: sterilization 時(shí)間: 2025-3-22 17:55
Circulating Vascular Endothelial Growth Factore with each other due to a lack of standardization of the pre-analytical phase. The chapter presents the main studies concerning anti-VEGF therapies; several studies evaluated the safety profile and activity of the combination of standard chemotherapy with new antiangiogenic agents. However, to date作者: gusher 時(shí)間: 2025-3-23 01:04 作者: 條街道往前推 時(shí)間: 2025-3-23 02:56 作者: OREX 時(shí)間: 2025-3-23 07:13 作者: 一夫一妻制 時(shí)間: 2025-3-23 11:17 作者: WITH 時(shí)間: 2025-3-23 14:57
https://doi.org/10.1007/978-3-322-94781-9, other regimens should not be withheld from women who cannot receive an anthracyline. Current clinical data also suggest a possible sensitivity to taxane-based therapy, especially when combined with an anthracycline. Trastuzumab-based therapy should be considered as first line therapy for women wit作者: adequate-intake 時(shí)間: 2025-3-23 21:11
Konfliktmanagement für Führungskr?fte lung, or liver. Recent clinical studies involving more than 3000 breast cancer patients demonstrated that presence of tumor cells in bone marrow at primary diagnosis is an independent prognostic factor for unfavorable clinical outcome. To date, sampling of bone marrow, however, is not a routine pro作者: 沒有準(zhǔn)備 時(shí)間: 2025-3-24 02:02 作者: Stable-Angina 時(shí)間: 2025-3-24 02:38 作者: 寄生蟲 時(shí)間: 2025-3-24 07:25 作者: 推延 時(shí)間: 2025-3-24 11:47 作者: colony 時(shí)間: 2025-3-24 18:28 作者: FAZE 時(shí)間: 2025-3-24 21:19 作者: affect 時(shí)間: 2025-3-25 02:25 作者: Rheumatologist 時(shí)間: 2025-3-25 04:08
https://doi.org/10.1007/978-3-322-94781-9 to date suggest that the proto-oncogene may be a predictive factor of response to several therapies that are commonly used to treat breast cancer. Tumors that are both hormone receptors and c-.-B2 positive may be associated with a relative resistance to tamoxifen. Preliminary data suggest that arom作者: 竊喜 時(shí)間: 2025-3-25 09:26
https://doi.org/10.1007/978-3-322-94781-9 in combination with chemotherapy in the treatment of metastatic, HER2 overexpressing breast cancer. This chapter reviews the history of the development of trastuzumab including the biology of HER signaling, the technical issues of antibody “humanization,” the diagnostic challenges in developing “ta作者: Chipmunk 時(shí)間: 2025-3-25 13:03
Konfliktmanagement bei Groupware,umerous central pathways determining the life and death of a cell. The information about the functional status of . has been considered to be extremely important for estimation of prognosis and the need of further treatment as well as for prediction of response and the selection of the optimal thera作者: 脫落 時(shí)間: 2025-3-25 16:35
Konfliktmanagement für Führungskr?ftenow be assessed in cancer patients using immunocytochemical and molecular assays able to detect even single metastatic cells. However, careful validation of technically confounding variables, including choice of detection antibody, preparation of cellular samples, and size of analyzed sample volumes作者: CHANT 時(shí)間: 2025-3-25 23:36 作者: prosthesis 時(shí)間: 2025-3-26 03:21 作者: 動(dòng)作謎 時(shí)間: 2025-3-26 06:54 作者: 痛苦一下 時(shí)間: 2025-3-26 09:24
Giampietro Gasparini,Daniel F. HayesIncludes supplementary material: 作者: 津貼 時(shí)間: 2025-3-26 15:38 作者: 前面 時(shí)間: 2025-3-26 20:42 作者: glamor 時(shí)間: 2025-3-26 22:39 作者: 充足 時(shí)間: 2025-3-27 01:32 作者: 形容詞詞尾 時(shí)間: 2025-3-27 08:30 作者: 閃光東本 時(shí)間: 2025-3-27 10:04
Assays for Gene AmplificationSince the approval of trastuzumab for the treatment of .-positive breast cancer (.), there has been an active debate as to the reproducibility and validity of the FDA-approved assays that detect . abnormalities in the tumor tissue. In this chapter, various clinical assays are compared focusing on practical issues.作者: arabesque 時(shí)間: 2025-3-27 16:23 作者: FLING 時(shí)間: 2025-3-27 18:12
Biomarkers in Breast Cancer978-1-59259-915-8Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 得意人 時(shí)間: 2025-3-27 22:54
Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically tic marker studies for breast cancer is inconsistent, and few such markers have been adopted for widespread use in clinical practice. This is problematic, as many patients are over-treated and many others are treated ineffectively. The deficiencies in clinical development of biomarkers may become mo作者: installment 時(shí)間: 2025-3-28 03:23 作者: Gene408 時(shí)間: 2025-3-28 09:32 作者: 古代 時(shí)間: 2025-3-28 13:58
Cell Kinetics in the past years many laboratories have set up and compared different approaches to measure the proliferation of tumor cells for clinical use. Although available results suggest that the majority of proliferation indices may help clinicians in treatment decision making, their clinical usefulness i作者: 釋放 時(shí)間: 2025-3-28 18:03 作者: 滔滔不絕地說 時(shí)間: 2025-3-28 21:09 作者: 舊病復(fù)發(fā) 時(shí)間: 2025-3-29 00:14
-B2 as a Therapeutic Target in combination with chemotherapy in the treatment of metastatic, HER2 overexpressing breast cancer. This chapter reviews the history of the development of trastuzumab including the biology of HER signaling, the technical issues of antibody “humanization,” the diagnostic challenges in developing “ta作者: 詩集 時(shí)間: 2025-3-29 06:30 作者: 五行打油詩 時(shí)間: 2025-3-29 07:44
Occult Metastatic Cells in Breast Cancer Patientsnow be assessed in cancer patients using immunocytochemical and molecular assays able to detect even single metastatic cells. However, careful validation of technically confounding variables, including choice of detection antibody, preparation of cellular samples, and size of analyzed sample volumes作者: 經(jīng)典 時(shí)間: 2025-3-29 13:18
Circulating HER2/neu, specifically directed to the extracellular domain (ECD) of the HER2/neu oncoprotein. The HER2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay. We performed an in-depth review of the peer-reviewed literature on circulating ECD levels with respect to prevalenc作者: 聯(lián)合 時(shí)間: 2025-3-29 16:36 作者: 不怕任性 時(shí)間: 2025-3-29 23:34
Book 2006or receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.作者: 付出 時(shí)間: 2025-3-30 00:52
https://doi.org/10.1007/978-3-322-85805-4formation. This chapter addresses some of these issues and presents initial analytical validation procedures of newly developed biomarker assays, the validation of already established assay procedures for routine use on a day-to-day basis, and finally discusses some aspects on adequate (external) quality control proficiency testing.作者: 歌曲 時(shí)間: 2025-3-30 04:12 作者: capsule 時(shí)間: 2025-3-30 09:55
Book 2006reast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new bi作者: 磨坊 時(shí)間: 2025-3-30 13:13
, as a Prognostic and Predictive Indicatorpy. The aim of this chapter is to evaluate why one of the most promising and most intensively studied markers is not recommended for routine clinical use to date. The pitfalls of . analysis and the challenges of well-designed . studies are elucidated and the need of carefully planned studies using an optimal . analysis method is pointed out.作者: Pillory 時(shí)間: 2025-3-30 16:58
